Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
0.8650
-0.0060 (-0.69%)
At close: Oct 2, 2026, 4:00 PM EDT
0.8719
+0.0069 (0.80%)
After-hours: Oct 2, 2026, 7:35 PM EDT
Akebia Therapeutics Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Akebia Therapeutics stock has a consensus rating of "Buy" and an average price target of $3.92. The average 1-year stock price forecast is 353.18% higher than the current stock price, while the lowest is $1.00 (+15.61%) and the highest is $6.00 (+593.64%).
Price Target: $3.92 (+353.18%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Akebia Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Buy Maintains $4 | Buy | Maintains | $4 | +362.43% | Sep 15, 2026 |
| Westpark Capital | Westpark Capital | Buy Initiates $4.5 | Buy | Initiates | $4.5 | +420.23% | Sep 8, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $4 | Buy | Maintains | $4 | +362.43% | Aug 17, 2026 |
| Leerink Partners | Leerink Partners | Hold Downgrades $1 | Hold | Downgrades | $1 | +15.61% | Aug 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $6 | Buy | Reiterates | $6 | +593.64% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
197.85M
from 236.20M
Decreased by -16.24%
Revenue Next Year
132.51M
from 197.85M
Decreased by -33.03%
EPS This Year
-0.16
from -0.02
EPS Next Year
-0.36
from -0.16
EPS and Forward PE are based on non-GAAP adjusted numbers.